• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Auto Inflammatory Disease - Pipeline Review, H2 2011 - Product Image

Auto Inflammatory Disease - Pipeline Review, H2 2011

  • Published: November 2011
  • 44 pages
  • Global Markets Direct

Auto Inflammatory Disease - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Auto Inflammatory Disease - Pipeline Review, H2 2011', provides an overview of the Auto Inflammatory Disease therapeutic pipeline. This report provides information on the therapeutic development for Auto Inflammatory Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Auto Inflammatory Disease. 'Auto Inflammatory Disease - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Auto Inflammatory Disease.
- A review of the Auto Inflammatory Disease products under READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Auto Inflammatory Disease Overview
Therapeutics Development
An Overview of Pipeline Products for Auto Inflammatory Disease
Auto Inflammatory Disease Therapeutics under Development by Companies
Auto Inflammatory Disease Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Auto Inflammatory Disease Therapeutics - Products under Development by Companies
Auto Inflammatory Disease Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Auto Inflammatory Disease Therapeutics Development
Emergent BioSolutions Inc.
Infinity Pharmaceuticals, Inc.
Biocon Limited
Palau Pharma S.A
Xencor, Inc.
PepTcell Limited
Auto Inflammatory Disease - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Anti-CD6 Monoclonal Antibody - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DD-2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
X1 Scorpion Therapeutics - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Xpro1595 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Kineret - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XOMA 052 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IPI-145 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ilaris - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug For Inflammation And Autoimmune Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Auto Inflammatory Disease Therapeutics – Drug Profile Updates
Auto Inflammatory Disease - Featured News
Sep 27, 2011: Novartis Receives Approval For Ilaris In Japan For Cryopyrin-Associated Periodic Syndrome
Sep 27, 2011: Novartis Receives Approval For Ilaris In Japan For Cryopyrin-Associated Periodic Syndrome
Jul 12, 2011: AnaptysBio Selects Anti-IL17 mAb Development Candidate To Treat Autoimmune And Inflammatory Conditions
Jun 23, 2011: Avila Presents Preclinical Data Of AVL-292 Demonstrating Suppression Of Autoimmune Disease Activity
Aug 26, 2010: Swedish Orphan Biovitrum Receives FDA Orphan Drug Designation For Kineret
Aug 26, 2010: Swedish Orphan Biovitrum’s Kineret Has Received Orphan Drug Designation In The USA
Jan 12, 2010: Novartis launches Ilaris in the UK
Oct 27, 2009: Regeneron Receives European Marketing Authorization For Rilonacept For Treatment Of Cryopyrin-Associated Periodic Syndromes
Jul 24, 2009: Regeneron Receives European Medicines Agency Positive Opinion For Marketing Authorization Of Rilonacept For The Treatment Of Cryopyrin-Associated Periodic Syndromes (CAPS)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Auto Inflammatory Disease, H2 2011
Products under Development for Auto Inflammatory Disease – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Emergent BioSolutions Inc., H2 2011
Infinity Pharmaceuticals, Inc., H2 2011
Biocon Limited, H2 2011
Palau Pharma S.A, H2 2011
Xencor, Inc., H2 2011
PepTcell Limited, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Auto Inflammatory Disease Therapeutics – Drug Profile Updates

List of Figures
Number of Products under Development for Auto Inflammatory Disease, H2 2011
Products under Development for Auto Inflammatory Disease – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos